Long-term follow-up in patients treated with methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) for transitional cell carcinoma of urinary bladder: Cause for concern-Reference-Cited by-同舟云学术

Long-term follow-up in patients treated with methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) for transitional cell carcinoma of urinary bladder: Cause for concern

Published:1989-12 Issue:6 Volume:34 Page:353-356
ISSN:0090-4295
Container-title:Urology
language:en
Short-container-title:Urology

Author:

Connor John P.,Olsson Carl A.,Benson Mitchell C.,Sawczuk Ihor S.,Rapoport Frederick

Publisher

Elsevier BV

Subject

Urology

Reference14 articles.

1. Learning to integrate systemic chemotherapy into a treatment plan for patients with advanced bladder cancer;Soloway;J Urol,1985

2. Chemotherapy for advanced urothelial cancer;Yagoda;Sem Urol,1983

3. Phase II trial of sequentially administered cisplatin, cyclophosphamide and doxorubicin for urothelial tract tumors;Schwartz;J Urol,1983

4. Vinblastine and methotrexate for advanced bladder cancer;Ahmed;J Urol,1985

5. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium;Sternberg;J Urol,1985

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The continuing role of chemotherapy in the management of advanced urothelial cancer;Therapeutic Advances in Urology;2018-11-28

2. The Rho-kinase inhibitor HA-1077 suppresses proliferation/migration and induces apoptosis of urothelial cancer cells;BMC Cancer;2014-06-07

3. The efficacy and safety of gemcitabine plus cisplatin regimen for patients with advanced urothelial carcinoma after failure of M-VAC regimen;International Journal of Clinical Oncology;2011-02-18

4. Successful Management of Metastatic Urothelial Carcinoma with Gemcitabine and Paclitaxel Chemotherapy in a Hemodialysis Patient;Urologia Internationalis;2011

5. Choosing chemotherapy in patients with advanced urothelial cell cancer who are unfit to receive cisplatin-based chemotherapy;Therapeutic Advances in Medical Oncology;2010-07-01